Craig Collard - Heron Therapeuti CEO Director
| HRTX Stock | USD 1.69 0.07 3.98% |
CEO
Craig Collard is CEO Director of Heron Therapeuti
| Age | 58 |
| Address | 4242 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 251 4400 |
| Web | https://www.herontx.com |
Craig Collard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Craig Collard against Heron Therapeuti stock is an integral part of due diligence when investing in Heron Therapeuti. Craig Collard insider activity provides valuable insight into whether Heron Therapeuti is net buyers or sellers over its current business cycle. Note, Heron Therapeuti insiders must abide by specific rules, including filing SEC forms every time they buy or sell Heron Therapeuti'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Craig Collard over a month ago Disposition of 13797 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 | ||
Craig Collard over three months ago Disposition of 62500 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 | ||
Craig Collard over six months ago Acquisition by Craig Collard of 13797 shares of Heron Therapeuti subject to Rule 16b-3 | ||
Craig Collard over six months ago Disposition of 62500 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 |
Heron Therapeuti Management Efficiency
The company has return on total asset (ROA) of (0.0231) % which means that it has lost $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.42 in 2024, whereas Return On Tangible Assets are likely to drop (0.52) in 2024. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 35.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.5 M in 2024.Similar Executives
| Found 7 records | CEO Age | ||
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Malte MD | Hookipa Pharma | 62 | |
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
Management Performance
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0231 |
Heron Therapeuti Leadership Team
Elected by the shareholders, the Heron Therapeuti's board of directors comprises two types of representatives: Heron Therapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heron. The board's role is to monitor Heron Therapeuti's management team and ensure that shareholders' interests are well served. Heron Therapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heron Therapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Executive Officer | ||
| Barry PharmD, Chairman CEO | ||
| Lisa Peraza, VP Officer | ||
| Chris Storgard, Chief Officer | ||
| Kimberly Manhard, Independent Director | ||
| Sean Ristine, Vice President - Human Resources | ||
| Michael Mathews, Senior Vice President - Pain Franchise | ||
| John Poyhonen, Independent Director | ||
| Thomas Ottoboni, Senior Vice President - Pharmaceutical and Preclinical Research and Development | ||
| Brett Fleshman, Chief Officer | ||
| David Szekeres, Senior Vice President General Counsel, Business Development, Corporate Secretary | ||
| Ira Duarte, Executive CFO | ||
| Ryan Craig, Vice Marketing | ||
| Craig Collard, CEO Director | ||
| Jeff Cohn, Assistant Director | ||
| Robert Sullivan, Senior Operations |
Heron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heron Therapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0231 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 364.4 M | ||||
| Shares Outstanding | 152.1 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 81.56 % | ||||
| Number Of Shares Shorted | 27.54 M | ||||
| Price To Earning | (5.15) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.